Abstract
Elevated eye pressure is the main risk factor for glaucoma; intraocular pressure rises when the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently, the main goal of medical treatment is the reduction of intraocular pressure. Five main classes of topical drugs are available; they include betablockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics and miotics. Beta-blockers and carbonic anhydrase inhibitors slow the formation of aqueous humor and may be considered as “inflow” drugs; the other three classes reduce the resistance to the drainage of aqueous humor and may be considered as “outflow” drugs. Despite the variety of drugs accessible in the market, there is a real need for ophthalmologists to have more potent medications for this disease. This review focuses on medical treatment of glaucoma with particular attention to novel molecules in pre-clinical or clinical development.
Keywords: Glaucoma, intraocular pressure, IOP lowering drugs, drug development.
Current Pharmaceutical Design
Title:Controversies in Glaucoma: Current Medical Treatment and Drug Development
Volume: 21 Issue: 32
Author(s): Claudio Bucolo, Chiara Bianca Maria Platania, Michele Reibaldi, Vincenza Bonfiglio, Antonio Longo, Salvatore Salomone and Filippo Drago
Affiliation:
Keywords: Glaucoma, intraocular pressure, IOP lowering drugs, drug development.
Abstract: Elevated eye pressure is the main risk factor for glaucoma; intraocular pressure rises when the ratio between aqueous humor formation (inflow) and its outflow is unbalanced. Currently, the main goal of medical treatment is the reduction of intraocular pressure. Five main classes of topical drugs are available; they include betablockers, carbonic anhydrase inhibitors, prostaglandin derivatives, sympathomimetics and miotics. Beta-blockers and carbonic anhydrase inhibitors slow the formation of aqueous humor and may be considered as “inflow” drugs; the other three classes reduce the resistance to the drainage of aqueous humor and may be considered as “outflow” drugs. Despite the variety of drugs accessible in the market, there is a real need for ophthalmologists to have more potent medications for this disease. This review focuses on medical treatment of glaucoma with particular attention to novel molecules in pre-clinical or clinical development.
Export Options
About this article
Cite this article as:
Bucolo Claudio, Platania Bianca Maria Chiara, Reibaldi Michele, Bonfiglio Vincenza, Longo Antonio, Salomone Salvatore and Drago Filippo, Controversies in Glaucoma: Current Medical Treatment and Drug Development, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909095553
DOI https://dx.doi.org/10.2174/1381612821666150909095553 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews Trends in the Pharmacology of Inflammatory and Allergic Eye Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protease-Activated Receptor 2: Are Common Functions in Glial and Immune Cells Linked to Inflammation-Related CNS Disorders?
Current Drug Targets Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Tomographic Imaging Methods and Gated Technique in Nuclear Cardiology: A Review on Current Status and Future Developments
Recent Patents on Medical Imaging Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Design and Development of Novel Azo Prodrugs using Various Permutations and Combinations of 5- and 4-Aminosalicylic Acids for Inflammatory Bowel Disease: A Colon-Targeted Approach
Inflammation & Allergy - Drug Targets (Discontinued) Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) The Fixed Combination Efficacy Assessment in Patients with Secondary Neovascular Glaucoma and Diabetes Mellitus
Current Diabetes Reviews